Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting

Phase 1

Phase 2

Abemaciclib & ElacestrantStudy of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Sponsor:

Stemline Therapeutics, Inc.

Code:

NCT05386108

Conditions

Breast Neoplasms

Brain Neoplasms

Neoplasms by Site

Neoplasms

Breast Diseases

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Elacestrant

Abemaciclib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-11. This information was provided to ClinicalTrials.gov by Stemline Therapeutics, Inc. on 2025-10-28.